Qinghai Spring Medicinal Resources Technology Valuation

Is 600381 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600381 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600381 (CN¥3.08) is trading below our estimate of fair value (CN¥9.69)

Significantly Below Fair Value: 600381 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600381?

Key metric: As 600381 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600381. This is calculated by dividing 600381's market cap by their current revenue.
What is 600381's PS Ratio?
PS Ratio	7x
Sales	CN¥251.20m
Market Cap	CN¥1.76b

600381 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.5x
Enterprise Value/EBITDA	-12.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 600381's PS Ratio compare to its peers?

The above table shows the PS ratio for 600381 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.4x
603139 Shaanxi Kanghui Pharmaceutical	2.5x	n/a	CN¥1.5b
002898 Sailong Pharmaceutical GroupLtd	6.6x	n/a	CN¥2.0b
605177 Zhejiang East Asia Pharmaceutical	1.6x	n/a	CN¥2.1b
600272 Shanghai Kai Kai Industry	2.7x	n/a	CN¥2.2b
600381 Qinghai Spring Medicinal Resources Technology	7x	n/a	CN¥1.8b

Price-To-Sales vs Peers: 600381 is expensive based on its Price-To-Sales Ratio (7x) compared to the peer average (3.4x).

Price to Sales Ratio vs Industry

How does 600381's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.30b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$790.12m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$413.04m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 600381 is expensive based on its Price-To-Sales Ratio (7x) compared to the CN Pharmaceuticals industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 600381's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600381 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600381's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

3.7%

7.9%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%